Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1454 ARTÍCULOS , VIENDO DEL 1066 AL 1080

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

Amyloid beta 1-42 and tau in the cerebrospinal fluid of renal failure patients for the diagnosis of Alzheimer's disease

Shea YF, Chu LW, Mok MY, Lam MF.

J Nephrol. 2014 Apr;27(2):217-20. doi: 10.1007/s40620-014-0043-6. Epub 2014 Jan 29.

Cognitive-behavioural group therapy improves a psychophysiological marker of stress in caregivers of patients with Alzheimer's disease

Aboulafia-Brakha T, Suchecki D, Gouveia-Paulino F, Nitrini R, Ptak R.

Aging Ment Health. 2014;18(6):801-8. doi: 10.1080/13607863.2014.880406. Epub 2014 Feb 5.

Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers

Perneczky R, Alexopoulos P, Kurz A.

Trends Mol Med. 2014 Jan;20(1):8-15. doi: 10.1016/j.molmed.2013.10.001.

Imaging biomarkers for amyloid: a new generation of probes and what lies ahead

Leuzy A, Zimmer ER, Bhat V, Rosa-Neto P, Gauthier S.

Int Psychogeriatr. 2014 May;26(5):703-7. doi: 10.1017/S1041610214000118. Epub 2014 Feb 13.

A systematic review of biomarkers for disease progression in Alzheimer's disease

McGhee DJ, Ritchie CW, Thompson PA, Wright DE, Zajicek JP, Counsell CE.

PLoS One. 2014 Feb 18;9(2):e88854. doi: 10.1371/journal.pone.0088854. eCollection 2014.

Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer's disease

Wang C, Yu JT, Wang HF, Jiang T, Tan CC, Meng XF, Soares HD, Tan L.

PLoS One. 2014 Feb 18;9(2):e89041. doi: 10.1371/journal.pone.0089041. eCollection 2014.

Lipidomics of Alzheimer's disease

Touboul D, Gaudin M.

Bioanalysis. 2014 Feb;6(4):541-61. doi: 10.4155/bio.13.346.

Epigenetic dysregulation in Alzheimer's disease: cause or consequence?

van den Hove DL, Kenis G, Rutten BP.

Epigenomics. 2014 Feb;6(1):9-11. doi: 10.2217/epi.13.84.

Diffusion tensor imaging of white matter degeneration in Alzheimer's disease and mild cognitive impairment

Amlien IK, Fjell AM.

Neuroscience. 2014 Sep 12;276:206-15. doi: 10.1016/j.neuroscience.2014.02.017. Epub 2014 Feb 27.

Detection of retinal nerve fiber layer degeneration in patients with Alzheimer's disease using optical coherence tomography: searching new biomarkers

Bambo MP, Garcia-Martin E, Pinilla J, Herrero R, Satue M, Otin S, Fuertes I, Marques ML, Pablo LE.

Acta Ophthalmol. 2014 Nov;92(7):e581-2. doi: 10.1111/aos.12374. Epub 2014 Mar 4.

Harmonized diagnostic criteria for Alzheimer's disease: recommendations

Morris JC, Blennow K, Froelich L, Nordberg A, Soininen H, Waldemar G, Wahlund LO, Dubois B.

J Intern Med. 2014 Mar;275(3):204-13. doi: 10.1111/joim.12199.

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M.

J Intern Med. 2014 Mar;275(3):251-83. doi: 10.1111/joim.12191.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias